See every side of every news story
Get Started
SubscribeLogin
Donald Trump
Hamas
US Politics
Israel-Hamas Conflict
Elon Musk
US Economy
CPAC
Ukraine War
Volodymyr Zelenskyy
Basketball
Baseball
Vladimir Putin
Published • loading... • Updated

Osteoporosis Biosimilar OK’d; New Endo Guidelines; A Hot Spot for Stealing Ozempic

Summary by MedPage Today
(MedPage Today) -- The FDA approved the denosumab biosimilar Ospomyv, interchangeable with Prolia, for preventing osteoporosis-related fracture and increasing bone

2 Articles

All
Left
Center
1
Right
MedPage TodayMedPage Today

Osteoporosis Biosimilar OK’d; New Endo Guidelines; A Hot Spot for Stealing Ozempic

(MedPage Today) -- The FDA approved the denosumab biosimilar Ospomyv, interchangeable with Prolia, for preventing osteoporosis-related fracture and increasing bone

·New York, United States
Read Full Article
ajmc.comajmc.com

Denosumab Biosimilars Approved With Interchangeability to Address Osteoporosis, Fracture Risk

The FDA approved Ospomyv and Xbryk, denosumab biosimilars that could expand access to treatment for osteoporosis, cancer-related bone loss, and other endocrine diseases.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

ajmc.com broke the news in on Tuesday, February 18, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Samsung

Samsung

FDA

FDA

United States

United States

News
For You
Search
BlindspotLocal